Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
52.02
-0.34 (-0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,364,210
Open
52.23
Bid (Size)
52.01 (1)
Ask (Size)
52.02 (3)
Prev. Close
52.36
Today's Range
51.53 - 53.22
52wk Range
32.83 - 53.00
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Breakout Biotech Stocks on Track to Double by 2032
Today 10:02 EDT
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.
Via
InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.
Via
Investor's Business Daily
Performance
YTD
+39.13%
+39.13%
1 Month
+17.45%
+17.45%
3 Month
+25.90%
+25.90%
6 Month
+39.13%
+39.13%
1 Year
+41.05%
+41.05%
More News
Read More
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
June 26, 2024
Via
Chartmill
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
June 24, 2024
Via
Investor's Business Daily
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
June 24, 2024
Via
Benzinga
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
June 24, 2024
Via
Chartmill
NASDAQ:HALO, a growth stock which is not overvalued.
June 04, 2024
Via
Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
May 14, 2024
Via
Chartmill
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
June 20, 2024
Via
Investor's Business Daily
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
June 19, 2024
Via
Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Via
InvestorPlace
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Via
Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
June 12, 2024
Via
Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
June 11, 2024
Via
Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
June 09, 2024
Via
Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
June 07, 2024
Via
Investor's Business Daily
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
June 07, 2024
Via
Benzinga
Halozyme Therapeutics +13% On Thursday: What's Going On?
June 06, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 06, 2024
Via
Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
June 06, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
June 04, 2024
Via
Benzinga
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
May 29, 2024
Via
Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
May 16, 2024
Via
Investor's Business Daily
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.